Skip to content
2000
Volume 23, Issue 2
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Background

Venous thromboembolism (VTE) prophylaxis is crucial for reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). This network meta-analysis was carried out to determine the most effective intervention among selective Xa inhibitors and low molecular weight heparins (LMWHs) for perioperative surgical thromboprophylaxis in major abdominal, pelvic, lumbar spine, and lower limb surgeries.

Methods

A systematic literature search was conducted for randomized controlled trials (RCTs) comparing selective factor Xa inhibitors, LMWHs, and placebo as thromboprophylaxis agents in major abdominal, pelvic, lumbar spine, and lower limb surgeries. A Bayesian network meta-analysis was performed to compare all interventions for the risk of developing DVT, VTE, major VTE, total bleeding, and major bleeding. The surface under the cumulative ranking curves was used to rank all interventions.

Results

Of 1788 retrieved references, 42 RCTs comparing 11 anticoagulants were included. As compared to enoxaparin, the risk of DVT was significantly reduced in patients treated with fondaparinux [RR: 0.53 (95% CrI: 0.31, 0.93)] and rivaroxaban [RR: 0.42 (95% CrI: 0.27, 0.64)]; VTE in patients treated with bemiparin [RR: 0.09 (95% CrI: 0, 0.7)], edoxaban [RR: 0.43 (95% CrI: 0.18, 0.96)], fondaparinux [RR: 0.55 (95% CrI: 0.34, 0.91)] and rivaroxaban [RR: 0.56 (95% CrI: 0.34, 0.85)]; major VTE in patients treated with rivaroxaban [RR: 0.26 (95% CrI: 0.11, 0.6)]. According to the surface under the cumulative ranking curves (SUCRA) value, fondaparinux and bemiparin increase the risk of serious bleeding more than other factor Xa inhibitors and LMWHs.

Conclusion

Rivaroxaban, fondaparinux, edoxaban, and bemiparin are superior perioperative thromboprophylaxis agents than enoxaparin in major surgeries. Fondaparinux and bemiparin have shown the highest risk of major bleeding compared to other factor Xa inhibitors and LMWHs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/0118715257331706240919172310
2025-06-01
2025-09-15

  • From This Site

    /content/journals/chamc/10.2174/0118715257331706240919172310
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GeertsW.H. HeitJ.A. ClagettG.P. PineoG.F. ColwellC.W. AndersonF.A.Jr WheelerH.B. Prevention of venous thromboembolism.Chest20011191132S175S10.1378/chest.119.1_suppl.132S 11157647
     [Google Scholar]
  2. CohenA.T. TapsonV.F. BergmannJ.F. GoldhaberS.Z. KakkarA.K. DeslandesB. HuangW. ZayaruznyM. EmeryL. AndersonF.A. Jr Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study.Lancet2008371961038739410.1016/S0140‑6736(08)60202‑0 18242412
     [Google Scholar]
  3. GeertsW.H. PineoG.F. HeitJ.A. BergqvistD. LassenM.R. ColwellC.W. RayJ.G. Prevention of Venous Thromboembolism.Chest20041263338S400S10.1378/chest.126.3_suppl.338S 15383478
     [Google Scholar]
  4. MeignanM. RossoJ. GauthierH. BrunengoF. ClaudelS. SagnardL. d’AzemarP. SimonneauG. CharbonnierB. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis.Arch. Intern. Med.2000160215916410.1001/archinte.160.2.159 10647753
     [Google Scholar]
  5. OteroR. UresandiF. CayuelaA. BlanquerJ. CabezudoM.A. De GregorioM.A. LoboJ.L. NauffalD. OribeM. Use of venous thromboembolism prophylaxis for surgical patients: A multicentre analysis of practice in Spain.Eur. J. Surg.2001167316316710.1080/110241501750099258 11316398
     [Google Scholar]
  6. YuH.T. DylanM.L. LinJ. DuboisR.W. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism.Am. J. Health Syst. Pharm.2007641697610.2146/ajhp060115 17189583
     [Google Scholar]
  7. EikelboomJ.W. MazzarolA. QuinlanD.J. BeaverR. WilliamsonJ. YiQ. HankeyG.J. Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.Haematologica2004895586593 15136222
     [Google Scholar]
  8. AminA. StemkowskiS. LinJ. YangG. Thromboprophylaxis rates in US medical centers: success or failure?J. Thromb. Haemost.2007581610161610.1111/j.1538‑7836.2007.02650.x 17663733
     [Google Scholar]
  9. TapsonV.F. DecoususH. PiniM. ChongB.H. FroehlichJ.B. MonrealM. SpyropoulosA.C. MerliG.J. ZotzR.B. BergmannJ.F. PavanelloR. TurpieA.G.G. NakamuraM. PiovellaF. KakkarA.K. SpencerF.A. FitzGeraldG. AndersonF.A.Jr Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism.Chest2007132393694510.1378/chest.06‑2993 17573514
     [Google Scholar]
  10. NutescuE.A. BurnettA. FanikosJ. SpinlerS. WittkowskyA. Pharmacology of anticoagulants used in the treatment of venous thromboembolism.J. Thromb. Thrombolysis2016411153110.1007/s11239‑015‑1314‑3 26780737
     [Google Scholar]
  11. O’DonnellM. WeitzJ.I. Thromboprophylaxis in surgical patients.Can. J. Surg.2003462129135 12691354
     [Google Scholar]
  12. MekajA. MekajY. DuciS. MiftariE. New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.Ther. Clin. Risk Manag.20151196797710.2147/TCRM.S84210 26150723
     [Google Scholar]
  13. TranA. FernandoS.M. CarrierM. SiegalD.M. InabaK. VogtK. EngelsP.T. EnglishS.W. KanjiS. KyeremantengK. LampronJ. KimD. RochwergB. Efficacy and safety of low molecular weight heparin versus unfractionated heparin for prevention of venous thromboembolism in trauma patients.Ann. Surg.20222751192810.1097/SLA.0000000000005157 34387202
     [Google Scholar]
  14. KumarA. TalwarA. FarleyJ.F. MuzumdarJ. SchommerJ.C. BalkrishnanR. WuW. Fondaparinux sodium compared with low-molecular-weight heparins for perioperative surgical thromboprophylaxis: A systematic review and meta-analysis.J. Am. Heart Assoc.2019810e01218410.1161/JAHA.119.012184 31070069
     [Google Scholar]
  15. MarcucciM. Etxeandia-IkobaltzetaI. YangS. GerminiF. GuptaS. AgarwalA. VentrescaM. TangS. MorganoG.P. WangM. AhmedM.M. NeumannI. IzcovichA. CrinitiJ. PopoffF. DevereauxP.J. DahmP. AndersonD. LavikainenL.I. TikkinenK.A.O. GuyattG.H. SchünemannH.J. VioletteP.D. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: Systematic review and network meta-analysis of randomised trials.BMJ2022376e06678510.1136/bmj‑2021‑066785 35264372
     [Google Scholar]
  16. KapoorA. EllisA. ShafferN. GurwitzJ. ChandramohanA. SaulinoJ. IshakA. OkubanjoT. HylekE. TrikalinosT.A. MichotaF. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: A network meta-analysis.J. Thromb. Haemost.201715228429410.1111/jth.13566 28102615
     [Google Scholar]
  17. RinaldiI. AminI.F. ShufiyaniY.M. DewantaraI.R. EdinaB.C. WinstonK. NurrobiY.A.S. Comparison of the efficacy and safety of rivaroxaban and enoxaparin as thromboprophylaxis agents for orthopedic surgery—systematic review and meta-analysis.J. Clin. Med.20221114407010.3390/jcm11144070 35887834
     [Google Scholar]
  18. LuX. LinJ. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: A systematic review and meta-analysis.BMC Musculoskelet. Disord.201819132210.1186/s12891‑018‑2215‑3 30193575
     [Google Scholar]
  19. NevillC.R. CooperN.J. SuttonA.J. A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis.J. Clin. Epidemiol.2023157839110.1016/j.jclinepi.2023.02.016 36870376
     [Google Scholar]
  20. McGuinnessL.A. HigginsJ.P.T. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-ofbias assessments.Res Synth Methods2021121556110.1002/jrsm.1411
     [Google Scholar]
  21. EsmonC.T. Basic mechanisms and pathogenesis of venous thrombosis.Blood Rev200923522522910.1016/j.blre.2009.07.002
     [Google Scholar]
  22. LassenM.R. GallusA. RaskobG.E. PineoG. ChenD. RamirezL.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.N. Engl. J. Med.2010363262487249810.1056/NEJMoa1006885 21175312
     [Google Scholar]
  23. SchulmanS. KearonC. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J. Thromb. Haemost.20053469269410.1111/j.1538‑7836.2005.01204.x 15842354
     [Google Scholar]
  24. HespanholL. VallioC.S. CostaL.M. SaragiottoB.T. Understanding and interpreting confidence and credible intervals around effect estimates.Braz. J. Phys. Ther.201923429030110.1016/j.bjpt.2018.12.006 30638956
     [Google Scholar]
  25. HackenbergerB.K. Bayes or not Bayes, is this the question?Croat. Med. J.2019601505210.3325/cmj.2019.60.50 30825279
     [Google Scholar]
  26. OwenR.K. BradburyN. XinY. CooperN. SuttonA. MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta.Res. Synth. Methods201910456958110.1002/jrsm.1373 31349391
     [Google Scholar]
  27. ChiocchiaV. NikolakopoulouA. HigginsJ.P.T. PageM.J. PapakonstantinouT. CiprianiA. FurukawaT.A. SiontisG.C.M. EggerM. SalantiG. ROB-MEN: A tool to assess risk of bias due to missing evidence in network meta-analysis.BMC Med.202119130410.1186/s12916‑021‑02166‑3 34809639
     [Google Scholar]
  28. ChiocchiaV. HollowayA. SalantiG. Semi-automated assessment of the risk of bias due to missing evidence in network meta-analysis: A guidance paper for the ROB-MEN web-application.BMC Med. Res. Methodol.202323122310.1186/s12874‑023‑02038‑9 37805460
     [Google Scholar]
  29. ErikssonB.I. BorrisL.C. DahlO.E. HaasS. HuismanM.V. KakkarA.K. MuehlhoferE. DierigC. MisselwitzF. KäleboP. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.Circulation2006114222374238110.1161/CIRCULATIONAHA.106.642074 17116766
     [Google Scholar]
  30. ErikssonB.I. BorrisL. DahlO.E. HaasS. HuismanM.V. KakkarA.K. MisselwitzF. KäleboP. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.J. Thromb. Haemost.20064112112810.1111/j.1538‑7836.2005.01657.x 16409461
     [Google Scholar]
  31. KakkarA.K. BrennerB. DahlO.E. ErikssonB.I. MouretP. MuntzJ. SoglianA.G. PapÁ.F. MisselwitzF. HaasS. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial.Lancet20083729632313910.1016/S0140‑6736(08)60880‑6 18582928
     [Google Scholar]
  32. KimS.M. MoonY.W. LimS.J. KimD.W. ParkY.S. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.Thromb. Haemost.2016115360060710.1160/th15‑07‑0527 26790579
     [Google Scholar]
  33. LassenM.R. AgenoW. BorrisL.C. LiebermanJ.R. RosencherN. BandelT.J. MisselwitzF. TurpieA.G.G. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.N. Engl. J. Med.2008358262776278610.1056/NEJMoa076016 18579812
     [Google Scholar]
  34. SamamaC.M. LaporteS. RosencherN. GirardP. LlauJ. MouretP. FisherW. Martínez-MartínJ. DuvergerD. DeygasB. PreslesE. CucheratM. MismettiP. Rivaroxaban or enoxaparin in nonmajor orthopedic surgery.N. Engl. J. Med.2020382201916192510.1056/NEJMoa1913808 32223113
     [Google Scholar]
  35. TangY. WangK. ShiZ. YangP. DangX. A RCT study of rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.Biomed. Pharmacother.20179298298810.1016/j.biopha.2017.05.107 28605879
     [Google Scholar]
  36. TurpieA.G.G. FisherW.D. BauerK.A. KwongL.M. IrwinM.W. KäleboP. MisselwitzF. GentM. BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.J. Thromb. Haemost.20053112479248610.1111/j.1538‑7836.2005.01602.x 16241946
     [Google Scholar]
  37. XieJ. MaJ. HuangQ. YueC. PeiF. Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: A pilot study.Med. Sci. Monit.20172370471110.12659/MSM.900059 28174415
     [Google Scholar]
  38. ErikssonB.I. BorrisL.C. FriedmanR.J. HaasS. HuismanM.V. KakkarA.K. BandelT.J. BeckmannH. MuehlhoferE. MisselwitzF. GeertsW. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.N. Engl. J. Med.2008358262765277510.1056/NEJMoa0800374 18579811
     [Google Scholar]
  39. TurpieA.G.G. LassenM.R. DavidsonB.L. BauerK.A. GentM. KwongL.M. CushnerF.D. LotkeP.A. BerkowitzS.D. BandelT.J. BensonA. MisselwitzF. FisherW.D. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial.Lancet200937396761673168010.1016/S0140‑6736(09)60734‑0 19411100
     [Google Scholar]
  40. ChinP.L. AminM.S. YangK.Y. YeoS.J. LoN.N. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: A randomised controlled trial.J. Orthop. Surg. (Hong Kong)20091711510.1177/230949900901700101 19398783
     [Google Scholar]
  41. HoY.H. Seow-ChoenF. LeongA. EuK.W. NyamD. TeohM.K. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients.Dis. Colon Rectum199942219620210.1007/BF02237127 10211496
     [Google Scholar]
  42. JørgensenP.S. StrandbergC. Wille-JørgensenP. TørholmC. NeergaardK. PaaskeB.P. RasmussenS.W. ChristensenS.W. MantoniM. ThamsenH. Early preoperative thromboprophylaxis with Klexane® in hip fracture surgery: A placebo-controlled study.Clin. Appl. Thromb. Hemost.19984214014210.1177/107602969800400213
     [Google Scholar]
  43. MarlovitsS. StriessnigG. SchusterR. StockerR. LuxlM. TrattnigS. VécseiV. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: A prospective, randomized, placebo-controlled study.Arthroscopy200723769670210.1016/j.arthro.2007.02.001 17637403
     [Google Scholar]
  44. BergqvistD. AgnelliG. CohenA.T. EldorA. NilssonP.E. Le Moigne-AmraniA. Dietrich-NetoF. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.N. Engl. J. Med.20023461397598010.1056/NEJMoa012385 11919306
     [Google Scholar]
  45. BergqvistD. BenoniG. BjörgellO. FredinH. HedlundhU. NicolasS. NilssonP. NylanderG. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.N. Engl. J. Med.19963351069670010.1056/NEJM199609053351002 8703168
     [Google Scholar]
  46. GoelD.P. BuckleyR. deVriesG. AbelsethG. NiA. GrayR. Prophylaxis of deep-vein thrombosis in fractures below the knee.J. Bone Joint Surg. Br.200991-B338839410.1302/0301‑620X.91B3.20820 19258618
     [Google Scholar]
  47. LapidusL.J. RosforsS. PonzerS. LevanderC. ElvinA. LärfarsG. de BriE. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: A randomized, placebo-controlled study.J. Orthop. Trauma2007211525710.1097/01.bot.0000250741.65003.14 17211270
     [Google Scholar]
  48. LapidusJ. L.; Ponzer, S.; Elvin, A.; Levander, C.; Lärfars, G.; Rosfors, S.; De Bri, E. Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: A randomized placebo-controlled, double-blind study.Acta Orthop.200778452853510.1080/17453670710014185 17966008
     [Google Scholar]
  49. LassenM.R. BorrisL.C. AndersonB.S. JensenH.P. BroH.P.S. AndersenG. PetersenA.O. SiemP. HørlyckE. JensenB.V. ThomsenP.B. HansenB.R. Erin-MadsenJ. MøllerJ.C. RotwittL. ChristensenF. NielsenJ.B. JørgensenP.S. PaaskeB. TørholmC. HvidtP. JensenN.K. NielsenA.B. AppelquistE. HansenO.G. MortensenD. TjalveE. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study.Thromb. Res.199889628128710.1016/S0049‑3848(98)00018‑8 9669750
     [Google Scholar]
  50. MichotM. ConenD. HoltzD. ErniD. ZumsteinM.D. RuflinG.B. RennerN. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery.Arthroscopy200218325726310.1053/jars.2002.30013 11877611
     [Google Scholar]
  51. TørholmC. BroengL. JørgensenP.S. BjerregaardP. JosephsenL. JørgensenP.K. HagenK. KnudsenJ.B. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study.J. Bone Joint Surg. Br.199173-B343443810.1302/0301‑620X.73B3.1670445 1670445
     [Google Scholar]
  52. SelbyR. GeertsW.H. KrederH.J. CrowtherM.A. KausL. SealeyF. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.J. Orthop. Trauma201529522423010.1097/BOT.0000000000000250 25900749
     [Google Scholar]
  53. BauerK.A. ErikssonB.I. LassenM.R. TurpieA.G.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.N. Engl. J. Med.2001345181305131010.1056/NEJMoa011099 11794149
     [Google Scholar]
  54. ErikssonB.I. BauerK.A. LassenM.R. TurpieA.G.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.N. Engl. J. Med.2001345181298130410.1056/NEJMoa011100 11794148
     [Google Scholar]
  55. LassenM.R. BauerK.A. ErikssonB.I. TurpieA.G.G. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison.Lancet200235993191715172010.1016/S0140‑6736(02)08652‑X 12049858
     [Google Scholar]
  56. TurpieA.G.G. BauerK.A. ErikssonB.I. LassenM.R. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial.Lancet200235993191721172610.1016/S0140‑6736(02)08648‑8 12049860
     [Google Scholar]
  57. LassenM.R. RaskobG.E. GallusA. PineoG. ChenD. PortmanR.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.N. Engl. J. Med.2009361659460410.1056/NEJMoa0810773 19657123
     [Google Scholar]
  58. GuntupalliS.R. BrenneckeA. BehbakhtK. TayebnejadA. BreedC.A. BabayanL.M. ChengG. RamzanA.A. WheelerL.J. CorrB.R. LefkowitsC. SheederJ. MatsuoK. FlinkD. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm.JAMA Netw. Open202036e20741010.1001/jamanetworkopen.2020.7410 32589230
     [Google Scholar]
  59. LassenM.R. RaskobG.E. GallusA. PineoG. ChenD. HornickP. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial.Lancet2010375971780781510.1016/S0140‑6736(09)62125‑5 20206776
     [Google Scholar]
  60. CamporeseG. BernardiE. NoventaF. BoscoM. MonteleoneG. SantoroL. BortoluzziC. FregujaS. NardinM. MarulloM. ZanonG. MazzolaC. DamianiG. ManiscalcoP. ImbertiD. LodigianiC. BecattiniC. TonelloC. AgnelliG. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study.Thromb. Haemost.20161162349355 27075710
     [Google Scholar]
  61. FujiT. FujitaS. KawaiY. NakamuraM. KimuraT. FukuzawaM. AbeK. TachibanaS. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V.Thromb. J.20151312710.1186/s12959‑015‑0057‑x 26269694
     [Google Scholar]
  62. AgnelliG. BergqvistD. CohenA.T. GallusA.S. GentM. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.Br. J. Surg.200592101212122010.1002/bjs.5154 16175516
     [Google Scholar]
  63. SamamaM. LensingA. BüllerH. BarreJ. VochelleN. BeauB. PlanèsA. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin.Thromb. Haemost.1999811222510.1055/s‑0037‑1614411 10348714
     [Google Scholar]
  64. HeitJ.A. ElliottC.G. TrowbridgeA.A. MorreyB.F. GentM. HirshJ. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.Ann. Intern. Med.20001321185386110.7326/0003‑4819‑132‑11‑200006060‑00002 10836911
     [Google Scholar]
  65. KolbG. BodamerI. GalsterH. SeidlmayerC. GrambachK. KoudelaK. EiseleR.R. BeckerC. PaalV. SpannagelU. BromJ. WeidingerG. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.Thromb. Haemost.200390611001105 14652643
     [Google Scholar]
  66. AlalafS.K. JawadA.K. JawadR.K. AliM.S. Al TawilN.G. Bemiparin for thromboprophylaxis after benign gynecologic surgery: A randomized clinical trial.J. Thromb. Haemost.201513122161216710.1111/jth.13164 26448633
     [Google Scholar]
  67. DuW. ZhaoC. WangJ. LiuJ. ShenB. ZhengY. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery.J. Orthop. Surg. Res.20151017810.1186/s13018‑015‑0223‑7 25998624
     [Google Scholar]
  68. RaskobG. CohenA.T. ErikssonB.I. PuskasD. ShiM. BocanegraT. WeitzJ.I. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.Thromb. Haemost.20101043642649 20589317
     [Google Scholar]
  69. Navarro-QuilisA. CastelletE. RochaE. Paz-JiménezJ. PlanèsA. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial.J. Thromb. Haemost.20031342543210.1046/j.1538‑7836.2003.00142.x 12871445
     [Google Scholar]
  70. WangZ. ZhengJ. ZhaoY. XiangY. ChenX. JinY. Effectiveness and tolerability of anticoagulants for thromboprophylaxis after major joint surgery: A network meta-analysis.Cell. Physiol. Biochem.20174251999202010.1159/000479840 28793291
     [Google Scholar]
  71. LiJ.L. ZhangM. MaiJ.L. MaY.H. GongD.W. ChenS. XiaoJ.C. WangH.B. Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: A systematic review and meta-analysis.Eur. Rev. Med. Pharmacol. Sci.2022261555405552 35993651
     [Google Scholar]
  72. LiangX. XieW. LinZ. LiuM. The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis.Anatol. J. Cardiol.20212527788 33583814
     [Google Scholar]
  73. CaldeiraD. RodriguesF.B. PintoF.J. FerreiraJ.J. CostaJ. Thromboprophylaxis With Apixaban in patients undergoing major orthopedic surgery: Meta-analysis and trial-sequential analysis.Clin Med Insights Blood Disord20171010.1177/1179545X17704660
     [Google Scholar]
  74. ManthaS. AnsellJ. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.J. Thromb. Thrombolysis201539215516510.1007/s11239‑014‑1102‑5 24989022
     [Google Scholar]
  75. FengW. WangX. HuangD. LuA. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.Pharmacol. Res.202116610543810.1016/j.phrs.2021.105438 33540046
     [Google Scholar]
  76. Ferriols-LisartR. Ferriols-LisartF. Jimnez-TorresV. Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.Pharm. World Sci.2002243879410.1023/A:1016187426582 12136745
     [Google Scholar]
  77. YangH. LiuM. YinW. ZhouL. ZuoX. Safety and efficacy of low molecular weight heparin for thromboprophylaxis in the elderly: A network meta-analysis of randomized clinical trials.Front. Pharmacol.20211278310410.3389/fphar.2021.783104 34955853
     [Google Scholar]
/content/journals/chamc/10.2174/0118715257331706240919172310
Loading
Factor Xa Inhibitors and Low Molecular Weight Heparins in Perioperative Surgical Thromboprophylaxis: A Network Meta-analysis
Cardiovasc. Hematol. Agents Med. Chem. 23, 112 (2025); https://doi.org/10.2174/0118715257331706240919172310
/content/journals/chamc/10.2174/0118715257331706240919172310
/content/journals/chamc/10.2174/0118715257331706240919172310
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article. PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): bleeding; deep vein thrombosis; Factor Xa inhibitors; low molecular weight heparins; meta-analysis; perioperative surgical thromboprophylaxis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test